Vironova BioAnalytics, a renowned provider of transmission electron microscopy (TEM) services, celebrates its acquisition led by QuatreLab, backed by Columbus Venture Partners, Accord Investment Partners, and Venture Targeter AB. This strategic move transforms it into QuTEM, reinforcing its commitment to high-quality TEM analyses under Good Manufacturing Practices (GMP) for pharmaceuticals. This evolution signifies growth and innovation, aligning with QuTEM’s vision to deliver cutting-edge solutions. Partnering with industry leaders brings new resources, empowering QuTEM to expand services, invest in technology, and maintain its focus on GMP-compliant TEM analyses, ensuring continued excellence for pharmaceutical research and quality control. Josefina Nilsson, QuTEM’s CEO, expresses eagerness to elevate service standards, while Javier García from Columbus Venture Partners highlights the potential for growth and support. This transition promises uninterrupted service excellence, assuring clients of QuTEM’s unwavering commitment to delivering exceptional results in drug development and quality assurance for the pharmaceutical sector.
BioAnalytics, a leading provider of transmission electron microscopy (TEM) services, is pleased to announce its acquisition led by QuatreLab (a quality control company created by Columbus Venture Partners) with the participation of Accord Investment Partners and Venture Targeter AB. This strategic move will enable Vironova BioAnalytics to enhance its capabilities and continue to deliver TEM analyses according to Good Manufacturing Practices (GMP) for the pharmaceutical industry. Following the completion of the acquisition, the company will be renamed and rebranded as QuTEM.
Vironova BioAnalytics has established a strong reputation as a trusted partner for pharmaceutical companies globally, known for its commitment to high-quality standards. This acquisition represents an important step in the company’s growth journey, fostering opportunities for innovation and expansion. The strategic decision to rebrand the company as QuTEM reflects the commitment to evolving and delivering cutting-edge TEM solutions to meet the evolving quality control needs of the pharmaceutical sector.
The partnership with Columbus Venture Partners through Quatre Lab, Accord Investment Partners, and Venture Targeter AB brings together valuable experience and new resources. This collaboration will empower QuTEM to expand its services, invest in advanced technologies, and accelerate development efforts. The company will maintain its focus on providing GMP-compliant TEM analyses crucial for pharmaceutical research, development, and quality control.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Josefina Nilsson, CEO of QuTEM (formerly Vironova BioAnalytics), expressed enthusiasm for the acquisition, saying, “We are excited to join forces with these new partners to allow us to provide the pharmaceutical industry with top-quality TEM services, and to expand our capabilities, drive innovation and better serve our clients.”
Javier García, co-founder and general partner of Columbus Venture Partners, also expressed his excitement about this acquisition. “Vironova BioAnalytics has a strong track record of delivering precise and reliable TEM analyses. We see potential in this collaboration and are committed to supporting the company’s growth and mission in the pharmaceutical sector.”
This acquisition and rebranding mark an inspiring new chapter for QuTEM. The company’s experienced team will continue to provide pharmaceutical clients with valuable insights and data to advance their drug development and quality assurance efforts. The company, alongside its new partners, is poised to drive innovation and make significant contributions to the pharmaceutical industry. Clients can expect a seamless transition, with QuTEM continuing to deliver the same level of excellence and reliability they have come to rely on from Vironova BioAnalytics.
Source: Biospace
